Regeneron Pharmaceuticals, INC 13F institutional holdings

Regeneron Pharmaceuticals, Inc. reported 3 holdings worth $177.2M for the period ended June 30, 2026.

Regeneron Pharmaceuticals discloses its equity investment portfolio as of March 31, 2026, featuring holdings in Adicet Bio and Intellia Therapeutics.

Regeneron Pharmaceuticals, Inc. filed its Q4 2025 13F-HR report, revealing holdings primarily in Intellia Therapeutics and Adicet Bio totaling over $33.7 million.

Regeneron Pharmaceuticals, Inc. filed its Form 13F-HR, revealing its equity investment portfolio totaling over $700 million as of September 30, 2025.

Regeneron Pharmaceuticals, Inc. has filed its Form 13F-HR, revealing its equity holdings totaling over $1.48 billion across four biotechnology and pharmaceutical companies as of June 30, 2025.

Regeneron Pharmaceuticals' latest 13F filing discloses over $1.2 billion in managed equity holdings as of March 31, 2025, with a focus on biotechnology companies.

Regeneron Pharmaceuticals' latest 13F filing reveals its equity holdings as of December 31, 2024, totaling over $1 billion.